Results 171 to 180 of about 2,826,854 (328)

Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: A single mode of inhibition for the three HIV enzymes? [PDF]

, 2006
María‐José Camarasa, Sonsoles Velázquez, Ana San‐Félix, María‐Jesús Pérez‐Pérez, Federico Gago   +4 more
openalex   +1 more source

Metabolic syndrome and Pathobiological Determination of Atherosclerosis in Youth risk score in adolescents with and without perinatally acquired HIV in the Cape Town Adolescent and Antiretroviral Cohort (CTAAC)‐Heart study

HIV Medicine, Volume 26, Issue 8, Page 1239-1250, August 2025.
Abstract Background Limited data exist describing metabolic syndrome (MetS) and Pathobiological Determinants of Atherosclerosis in Youth (PDAY) coronary arteries (CA) and abdominal aorta (AA) risk scores in youth with HIV in sub‐Saharan Africa.
Sahera Dirajlal‐Fargo, Mothabisi Nyathi, Shan Sun, Lauren Balmert Bonner, Morné Kahts, Nana Akua Asafu‐Agyei, Nomawethu Jele, Emma Carkeek, Justine Legbedze, Grace A. McComsey, Matthew Feinstein, Landon Myer, Ntobeko A. B. Ntusi, Heather J. Zar, Jennifer Jao   +14 more
wiley   +1 more source

Therapeutic Opportunities in Infectious Diseases: Highlights from the Society of Medicines Research Symposium, held on March 14th 2013 at the National Heart & Lung Institute, London, UK [PDF]

, 2013
Alderton, W K, Anderson, Rosaleen, Collingwood, S P, Pryde, D C   +3 more
core   +1 more source

Discovery of a small-molecule HIV-1 integrase inhibitor-binding site [PDF]

, 2006
Laith Q. Al‐Mawsawi, Valery Fikkert, Raveendra Dayam, Myriam Witvrouw, Terrence R. Burke, Christoph H. Borchers, Nouri Neamati   +6 more
openalex   +1 more source

Comparison of treatment‐emergent resistance‐associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor‐based single‐tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta‐analysis

HIV Medicine, Volume 26, Issue 8, Page 1184-1198, August 2025.
Abstract Objective This study evaluated rates of treatment‐emergent resistance‐associated mutations (TE‐RAMs) and discontinuation due to adverse events (DC‐AEs) across integrase strand transfer inhibitor (INSTI)‐based single‐tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV.
Ishfaq Rashid, Nathan R. Unger, Connor Willis, Teerapon Dhippayom, Moti Ramgopal, Elizabeth M. Sherman, Nicholas Yared, Rachel Safran, Edwin Swiatlo, Amy R. Weinberg, Soodi Navadeh, Howard Weston Schmutz, Nathorn Chaiyakunapruk   +12 more
wiley   +1 more source

Development of H51Y and E157Q mutations for integrase inhibitor resistance in a patient undergoing treatment for pulmonary tuberculosis: A case report. [PDF]

SAGE Open Med Case Rep, 2023
Farias LABG, Saboya MF, Ponte Fernandes N, Perdigão Neto LV, de Arruda EAG.   +4 more
europepmc   +1 more source

Novel HIV Integrase Inhibitors with Anti-HIV Activity: Insights into Integrase Inhibition from Docking Studies [PDF]

, 2006
Arthur G. Cox, Vasu Nair
openalex   +1 more source

Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment‐experienced people living with HIV: A feasibility survey

HIV Medicine, Volume 26, Issue 8, Page 1251-1257, August 2025.
Abstract Introduction As life expectancy among persons with HIV on antiretroviral therapy (ART) is increasing, comorbidities and polypharmacy increase. Drug–drug interactions (DDIs) are common among persons with HIV with a history of virological failure, since many are receiving boosted ART.
Marie Ballif, Manuela Correia da Silva Saúde, David Haerry, Marcel Stoeckle, Patrick Schmid, Dominique Braun, Alexandra Calmy, Gilles Wandeler, Bernard Surial   +8 more
wiley   +1 more source

Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137) [PDF]

, 2007
Kazuya Shimura, Eiichi Kodama, Yasuko Sakagami, Yumi Matsuzaki, Wataru Watanabe, Kazunobu Yamataka, Yasuo Watanabe, Yoshitsugu Ohata, Satoki Doi, Motohide Sato, Mitsuki Kano, Satoru Ikeda, Masao Matsuoka   +12 more
openalex   +1 more source

Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV

HIV Medicine, Volume 26, Issue 8, Page 1267-1288, August 2025.
Abstract Introduction Randomized controlled trial evidence suggests that long‐acting injectable (LA‐I) cabotegravir and rilpivirine (CAB+RPV) has similar virological failure (VF) rates to daily oral therapy, but clinical practice evidence is lacking. Integrase inhibitor (INI) resistance may limit future therapy.
Kyle Ring, Alexa Elias, Megan Devonald, Melanie Smuk, Chloe Orkin   +4 more
wiley   +1 more source